Peter Zweifel
Reexamining Drug Regulation from the Perspective of Innovation Policy: Comment
- article PDF
- available
- 10.1628/093245604773861177
Due to a system change, access problems and other issues may occur. We are working with urgency on a solution. We apologise for any inconvenience.
Summary
Authors/Editors
Reviews
Summary
This is a very colorful paper that makes for interesting reading. The author shows that the U. S. Food and Drug Administration (FDA) increasingly does not decide about market access to drugs only, but influences the innovation process as a whole. And although »information« does not appear in the title of the paper, the distribution of knowledge as affected by the FDA plays an important role at several stages of this process. For this reason, the body of this commentary is arranged according to the stages of the innovation process.